GNPDA2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the GNPDA2 gene has been disrupted in Jurkat human T lymphocytes. This heterogeneous loss-of-function model enables population-based study of GNPDA2-dependent processes, avoiding clonal selection bias. It is designed for investigating hexosamine pathway biology and glycosylation in a widely used T cell model.
Jurkat cells, derived from peripheral blood of a 14-year-old boy with acute T cell leukemia, are immortalized T lymphocytes that serve as a paradigmatic model for T cell signaling, HIV infection, and cancer research. They recapitulate key aspects of TCR-mediated activation, cytokine production, and apoptosis, and their genetic tractability facilitates gene disruption studies. The use of Jurkat as the host cell line allows exploration of the interplay between hexosamine metabolism and T cell function.
GNPDA2 encodes glucosamine-6-phosphate deaminase 2, which catalyzes the conversion of glucosamine-6-phosphate to fructose-6-phosphate and ammonia within the hexosamine biosynthesis pathway (HBP). Acting downstream of glutamine:fructose-6-phosphate amidotransferase (GFPT1/2) and glucosamine-6-phosphate N-acetyltransferase (GNPNAT1), GNPDA2 regulates flux toward UDP-N-acetylglucosamine (UDP-GlcNAc) synthesis. UDP-GlcNAc is a vital substrate for N-glycosylation, O-GlcNAcylation, and glycoprotein maturation, processes influenced by upstream regulators such as nutrient availability and the unfolded protein response. GNPDA2 interacts with HBP enzymes including GNPNAT1 and potentially O-GlcNAc transferase (OGT). Disruption of GNPDA2 impairs glucosamine-6-phosphate deamination, reducing UDP-GlcNAc levels and thereby altering glycosylation-dependent protein folding, stability, and signaling.
In Jurkat cells, GNPDA2 loss is expected to disrupt TCR signaling and metabolic reprogramming by limiting substrate availability for O-GlcNAcylation and N-glycosylation of key signaling molecules. Proper glycosylation is essential for TCR complex assembly, surface expression, and downstream kinase activation. Reduced UDP-GlcNAc may attenuate O-GlcNAc modification of transcription factors and adaptor proteins, impacting proliferation, cytokine production, and survival pathways. This polyclonal knockout model enables examination of how hexosamine flux governs immune cell activation and leukemia cell growth, highlighting potential HBP vulnerabilities in T cell malignancies.
Research applications include dissecting hexosamine pathway contributions to T cell activation and signaling, metabolic profiling of leukemia, and investigating glycosylation-dependent regulatory mechanisms. The model supports assays such as western blotting, RT-qPCR, flow cytometry, lectin binding, metabolic flux analysis, and proliferation assays to characterize the knockout phenotype. The polyclonal format facilitates robust population-level analyses of metabolic and signaling changes. For further technical information or to discuss specific experimental applications, please contact Ascent Research.
